Program Director/Principal Investigator (Norenberg, Jeffrey, P.):
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Jeffrey P. Norenberg
Professor and Director, Radiopharmaceutical Sciences
Associate Director, New Mexico Center for Isotopes in
Medicine
Director, Keck-UNM Small-Animal Imaging Resource
eRA COMMONS USER NAME (credential, e.g., agency login)
jpnoren
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
University of Nebraska, Lincoln, NE
UNM, Albuquerque, NM
UNM , Albuquerque, NM
UNM, Albuquerque, NM
NIH, Bethesda, MD
NIH, Bethesda, MD
University of Washington, Seattle, WA
DEGREE
(if applicable)
YEAR(
s)
B.S.
B.S.
M.S.
Residency
PHS - COSTEP
PHS - COSTEP
PharmD.
1986
1990
1991
1991
1989
1990
2001
FIELD OF STUDY
Biology
Pharmacy
Pharmaceutical Sciences
Nuclear Pharmacy
Nuclear Pharmacy
PET Nuclear Pharmacy
Clinical Pharmacy
A. Personal Statement
My research background in radiopharmaceutical discovery and development provides me with the knowledge
and skills to develop molecular imaging probes designed to target unique cellular biochemical and
pathophysiologic expressions of disease. I am a member of the Cancer Biology Program and have
developed novel imaging agents targeting lymphoma and leukemia. I have experience in the preparation and
characterization of targeted molecular imaging probes; their characterization using in vitro and in vivo
methods and models; small-animal biodistribution and imaging studies; image processing, and image data
analysis to demonstrate cellular and tissue response following exposure to radiolabeled compounds. I have
led research aimed at the discovery and development of radiotracers and radiopharmaceuticals. My
experience as an Authorized User and radioactive permit holder will ensure that the aims are conducted in
full compliance with all applicable standards of radiation safety and the ethical treatment of animals in
research. In summary; my record of sustained, successful, and productive research in the area of
radiopharmaceutical discovery and development, and in vivo small-animal PET/SPECT/CT molecular
imaging has prepared me to perform as a co-director of the KECK-UNM Animal Models and Imaging
Resource (KUMAIR) on this project where our goal is to provide high quality and cost-effective services in
animal models for cancer. From the inception of KUMAIR I have had the opportunity to work closely with Dr.
Hathaway to engage interested investigators to determine how to best meet their individual needs on the
design, execution, and data analysis of experiments involving state-of-the-art PET/SPECT/CT
radiopharmaceutical imaging in small animals.
B. Positions and Honors
Positions and Employment
Positions and Employment
1985
1990 - 1991
1991 - 1993
1993
1993 - 1994
1994 - 2004
1998 - Present
2002 - Present
2003 - Present
2004 - 2009
2004 - Present
2006 - Present
2009 - Present
Undergraduate Teaching Assistant, Dept of Biology, University of Nebraska, Lincoln, NE
Grad Research Assistant, Radiopharmacy, College of Pharmacy, UNM, Albuquerque, NM
Instructor, Department of Radiology, Tufts University School of Medicine, Boston, MA
Lecturer I, College of Pharmacy, UNM, Albuquerque, NM
Clinical Assistant Professor, College of Pharmacy, UNM, Albuquerque, NM
Assistant Professor, College of Pharmacy UNM, Albuquerque, NM
Director, Radiopharmaceutical Sciences Program UNM, Albuquerque, NM
Executive Director and Chairman, Board of Directors, National Assoc. Nuclear Pharmacies
Associate Member, Cancer Research and Treatment Center, UNM, Albuquerque, NM
Associate Professor, College of Pharmacy, UNM, Albuquerque, NM
Associate Director, New Mexico Center for Isotopes in Medicine, UNM, Albuquerque, NM
Director, KECK UNM Small Animal Imaging Resource UNM, Albuquerque, NM
Professor, College of Pharmacy, UNM, Albuquerque, NM
PHS 398/2590 (Rev. 06/09)
Page
1
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
Honors
1985
1989 - 1991
1990
1990
2000
2003
Sarah Welch Outstanding Achievement Scholarship
Dean’s List, College of Pharmacy, University of New Mexico
United States Public Health Service Outstanding Achievement Citation
Department of Interior Meritorious Service Commendation
Fellow, American Society of Health System Pharmacists
Fellow, American Pharmaceutical Association
Other Experience and Professional Memberships
American Associate for Cancer Research (AACR), Member 2005 - present
Nuclear Science Advisory Committee (NSAC) - Isotope Subcommittee, 2008 - 2011
Society of Nuclear Medicine, 1990 - present
Molecular Imaging Center of Excellence, Education Task Force, Member 2007 - present
Commission on Radiopharmaceuticals, Chair 2008 - present
Board of Directors 2009 – 2012
Radiopharmaceutical Sciences Council (RPSC), Member 1994 - present
Immediate Past-President 2009-2010
President 2008-2009
Educational Program Organizer
Moderator, Oncology-Clinical Session. 55th Society of Nuclear Medicine Annual Meeting.
C.
1.
2.
3.
4.
5.
6.
7.
8.
9.
Selected Peer-reviewed Publications (Selected from 40 peer-reviewed publications)
Most relevant to the current application
Kuehl PJ, Anderson T, Candelaria G, Gershman B, Harlin K, Hesterman JY, Holmes T, Lackas C,
Norenberg JP, Yu H, McDonald JD. Regional Particle Size Dependent Deposition of Inhaled Aerosols In
Rats And Mice. Inhalation Toxicology 2012;24(1):27-35 (PMID: 22145784)
Nayak TK, Dennis MK, Ramesh C, Burai R, Atcher RW, Sklar LA, Norenberg JP, Hathaway HJ, Arterburn
JB, Prossnitz ER. Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111inlabeled nonsteroidal imaging agents. ACS Chem Biol 2010; 5(7):681-690.
Aillon KL, El-Gendy N, Dennis C, Norenberg, JP, McDondald J, Berkland C. Iodinated NanClusters as an
Inhaled Computed Tomography Contrast Agent for Lung Visualization. Molecular Pharmaceutics,
2010;7(4):1274-1282.
Honggang Y, Hoppin J, Harlin, K, McDonald J, Kuehl P, Anderson TL, Lackas C, Gershman B, Candelaria
G, Hesterman JY, Norenberg JP. Implementation Of A 3D Topographic Thinning Model For Assessing
Aerosol Deposition Of Radioactive Assays In Small-Animal CT/SPECT Imaging. IEEE Nuclear Science
Symposium Conference Record (NSS/MIC) 2009;3705-3709.
Beregeron M, Cadorette J, Beaudoin, Lepage MD, Robert G, Selivanov V, Tétrault M-A, Viscogliosi N,
Norenberg JP, Fontaine R, Lecomte R. Performance Evaluation of the LabPET APD-Based Digital PET
Scanner, IEEE Transactions on Nuclear Science, 2009;56(1):10-16.
Bergeron M, Cadorette J, Beaudoin JF, Rousseau JA, Dumoulin M, Lepage MD, Robert G, Selivanov V,
Tétrault MA, Viscogliosi N, Dumouchel T, Thorn S, Dasilva J, Dekemp RA, Norenberg JP, Fontaine R,
Lecomte R. Performance Evaluation Of The Labpet™ APD-Based Digital PET Scanner. IEEE
2007;6:4185-4191.
Poria RB, Norenberg JP, Anderson TL, Wagner CR, Arterburn JB, Larson RS. Characterization of 177Lulabeled small molecule for non-invasive tumor imaging and radiotherapy. Cancer Biotherapy &
Radiopharmaceuticals, 2006:21 (5): 418-426.
Norenberg JP, Krenning BJ, Konigs IG, Kusewitt DF, Nayak TK, Anderson TL, deJong M, Garmestani K,
Brechbiel MW, Kvols LK. 213Bi-DOTATOC Peptide Receptor Radionuclide Therapy of Neuroendocrine
Tumors in a Pre-Clinical Animal Model. Clinical Cancer Research 12(3) February 1:897-903, 2006.
Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER, PreClinical Development Of A Neutral, Estrogen Receptor-Targeted, Tridentate 99mTc(I) Estradiol Pyridin-2yl Hydrazine Derivative For Imaging Of Breast And Endometrial Cancers. Journal Of Nuclear Medicine
2008; 49 (6):978–986.
PHS 398/2590 (Rev. 06/09)
Page
2
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
D. Research Support
Ongoing Research Support
CCSG P30 CA118100 (Willman)
09/01/10-8/31/15
NCI/NIH
UNM Comprehensive Cancer Center
Purpose of Section 9.1.6 Shared Resource: The Keck-UNM small animal models and imaging resource provides value
to members of the UNM Cancer Center by providing a comprehensive service in the development and use of animal
models for basic and pre-clinical cancer research.
Role: Co-Director KUMAIR
Number not assigned (Norenberg)
Invicro, LLC
12/1-3/12
68Ga labeling of DOTA-conjugated peptides– Task 17
Purpose: The main goal of this project is the optimization and kit formulation of a 68Ga labeled DOTA
conjugated peptide.
Role: PI
Completed Research Support
Number not assigned (Norenberg)
7/08-4/09
Lovelace Respiratory Research Institute
Imaging the Distribution and Fate of Botulinum Toxin Heavy Chain in Mice A Pilot Study Continued.
The purpose of this grant is to obtain information on imaging botulinum toxin heavy chain in mice using
SPECT.
Role: PI
Number not assigned (Norenberg)
7/08-7/10
Bioscan Inc.
A University of New Mexico contract for radiopharmaceutical imaging.
The purpose of this grant is to perform quantification of a SPECT imaging modality.
Role: PI
Number not assigned (Norenberg)
6/09-11/09
NuView Radiopharmaceuticals, Inc.
In Vivo evaluation of DOTA-alkylamino-NorBIRT, a LFA-1 Targeted Radiopharmaceutical using different
animal models of disease.
The purpose of this grant was to investigate a novel imaging agent to target leukemia, lymphoma, and
inflammation.
Role: PI
Number not assigned (Norenberg)
6/09-7/09
Savara Pharmaceuticals
Inhaled Contrast Agent Imaging.
Purpose: The purpose of this grant was to investigate a potential lung imaging contrast agent in mice.
Role: PI
#DE-Number not assigned (Burchiel, Atcher LANL)
10/09-9/10
Los Alamos National Laboratory, Biosciences Division, DOE OBER subaward
Mix Evolution Experimental Investigation.
The purpose of this grant is for a UNM contract for radiopharmaceutical support to LANL.
Role: Co-Investigator
Number not assigned (Norenberg)
2/10-4/11
Pulmatrix
Imaging Novel Radiopharmaceuticals in Ferrets (Task 1 and Task 2).
PHS 398/2590 (Rev. 06/09)
Page
3
Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle):
The purpose of this grant was to evaluate the uptake of a novel Tc-99m radiotracer in the lungs of healthy
ferrets.
Role: PI
Number not assigned (Norenberg)
6/10-12/10
Invicro, LLC
In-111 Peptide Distribution in Normal Mice.
The purpose of this grant was to evaluate the uptake of a novel In-111 labeled peptide in a normal mouse
model.
Role: PI
Number not assigned (Norenberg)
10/10-3/11
Invicro, LLC
SPECT Imaging of I-125 Labeled Antibodies in a Mouse Model.
The purpose of this grant was to evaluate the uptake of a novel I-125 labeled antibody in a mouse model of
cancer.
Role: PI
# DE-FG02-08ER64580 (Burchiel)
11/08-12/11
Department of Energy award
Purpose:The major goal of this grant is to develop the New Mexico Center for Isotopes and Medicine.
Role: Co-PI
Number not assigned (Norenberg)
1/10-5/11
Ligocyte Pharmaceuticals, Inc.
A Quantitative Comparison of a 99m-Tc Compound in the Lungs of Conscious Rabbits N=4
Purpose: The major goal of this project is to study the uptake of a novel imaging agent in rabbits during imaging.
Role: PI
Number not assigned (Norenberg)
1/11-7/11
Invicro, LLC
Indium-111 labeling of 2 DOTA compounds.
Purpose: The major goal of this project is to develop a labeling method for multiple compounds using the radioisotope
Indium-111.
Role: PI
Number not assigned (Norenberg)
Invicro, LLC
1/12-6/12
Radiolabeling and SPECT/CT Imaging of NBN, tyrosine, and an anti-RET antibody for labeling validation,
study of in vivo targeting and pharmacokinetics – Task 12.
Purpose: The major goal of this project is to develop a labeling method for multiple compounds using the radioisotope
Indium-111 and I-125 and to perform imaging protocols in tumor and normal animals.
Role: PI
Number not assigned (Norenberg)
Invicro, LLC
11/11-5/12
Laboratory testing of Radiolabeling and SPECT/CT Imaging of NBN and tyrosine for labeling validation,
clinical isotope selection, and multi-dose stud – Task 10
Purpose: The major goal of this project is to develop a labeling method for multiple compounds using the radioisotope
Indium-111 and I-125.
Role: PI
Number not assigned (Norenberg)
Invicro, LLC
12/1-3/12
DOTA-peptides Ahx-STp (5-18) – Task 11
Purpose: The major goal of this project is to develop a labeling method for peptides using the radioisotope Indium-111.
Role: PI
PHS 398/2590 (Rev. 06/09)
Page
4
Continuation Format Page